Allurion Technologies receives continued listing standards notice from NYSE

Allurion Technologies received written notice from the NYSE that it is not in compliance with the NYSE’s continued listing standards because the average market capitalization of the company was less than $50.0M over the consecutive 30 trading-day period ended August 29 and the company’s last reported stockholders’ equity as of August 29, 2024 was less than $50.0M. The notice does not result in the immediate delisting of the company’s common stock from the NYSE. Within 45 days from receipt of the Notice, the company intends to submit a plan to the NYSE advising it of the definitive action the company has taken, is taking, or plans to take that would bring it into conformity with the continued listing standards. If the NYSE accepts the company’s plan, the company’s common stock will continue to be listed and traded on the NYSE during the 18-month cure period, subject to the company’s compliance with other NYSE continued listing standards and continued periodic review by the NYSE of the Company’s progress with respect to its plan. The Notice has no immediate impact on the listing of the Company’s common stock, which will continue to be listed and traded on the NYSE during such cure period.